Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease.
CORE-IBD Collaborators; Ma C, Hanzel J, Panaccione R, Sandborn WJ, D'Haens GR, Ahuja V, Atreya R, Bernstein CN, Bossuyt P, Bressler B, Bryant RV, Cohen B, Colombel JF, Danese S, Dignass A, Dubinsky MC, Fleshner PR, Gearry RB, Hanauer SB, Hart A, Kotze PG, Kucharzik T, Lakatos PL, Leong RW, Magro F, Panés J, Peyrin-Biroulet L, Ran Z, Regueiro M, Singh S, Spinelli A, Steinhart AH, Travis SP, van der Woude CJ, Yacyshyn B, Yamamoto T, Allez M, Bemelman WA, Lightner AL, Louis E, Rubin DT, Scherl EJ, Siegel CA, Silverberg MS, Vermeire S, Parker CE, McFarlane SC, Guizzetti L, Smith MI, Vande Casteele N, Feagan BG, Jairath V. CORE-IBD Collaborators, et al. Among authors: vande casteele n. Gastroenterology. 2022 Oct;163(4):950-964. doi: 10.1053/j.gastro.2022.06.068. Epub 2022 Jul 3. Gastroenterology. 2022. PMID: 35788348 Free article.
Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.
Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernolle G, Jürgens M, Ferrante M, Ballet V, Wollants WJ, Cleynen I, Van Steen K, Gils A, Rutgeerts P, Vermeire S, Van Assche G. Drobne D, et al. Among authors: vande casteele n. Clin Gastroenterol Hepatol. 2015 Mar;13(3):514-521.e4. doi: 10.1016/j.cgh.2014.07.027. Epub 2014 Jul 25. Clin Gastroenterol Hepatol. 2015. PMID: 25066841
An update on anti-TNF agents in ulcerative colitis.
Samaan MA, Bagi P, Vande Casteele N, D'Haens GR, Levesque BG. Samaan MA, et al. Among authors: vande casteele n. Gastroenterol Clin North Am. 2014 Sep;43(3):479-94. doi: 10.1016/j.gtc.2014.05.006. Gastroenterol Clin North Am. 2014. PMID: 25110254 Review.
A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis.
Arias MT, Vande Casteele N, Vermeire S, de Buck van Overstraeten A, Billiet T, Baert F, Wolthuis A, Van Assche G, Noman M, Hoffman I, D'Hoore A, Gils A, Rutgeerts P, Ferrante M. Arias MT, et al. Among authors: vande casteele n. Clin Gastroenterol Hepatol. 2015 Mar;13(3):531-8. doi: 10.1016/j.cgh.2014.07.055. Epub 2014 Aug 10. Clin Gastroenterol Hepatol. 2015. PMID: 25117777
144 results